Korea FDA Rebuts Reports Of Compulsory Licensing For Roche's Tamiflu
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Korea FDA rejected Friday local press reports that the Korean government - jittery over the rising number of local people infected with A/H1N1- will soon exercise the option of "compulsory licensing" to produce generic versions of Roche's Tamiflu (oseltamivir)
You may also be interested in...
Korea’s Celltrion Advances Its First Novel Therapy, Universal Influenza Treatment
Beyond its main focus of biosimilars, Celltrion is pursuing an influenza therapy that would be its first original product.
South Korea Discusses Opening State-owned Pharma For Stable Drug Supply
The president of the National Health Insurance Service told lawmakers his agency is assessing the feasibility of a state-owned pharma, which the domestic industry group said could put a pinch on reimbursement negotiations.
GSK To Supply Korea With 3 Million Doses of A/H1N1 Flu Vaccine By Year End
SEOUL - As part of its bid to better tackle spreading A/H1N1 flu infections, South Korea's Ministry for Health, Welfare and Family Affairs has asked GlaxoSmithKline to supply three million doses of its A/H1N1 flu vaccine within the year, rather than next year as originally planned